MyRisk™
Hereditary Cancer Test

Positive result

Understanding a positive result

A guide to understanding risk and taking action

Myriad genetics

Health. Illuminated.

Positive result

Understanding your Myriad MyRisk™ hereditary cancer test result

Your Myriad Genetics MyRisk Hereditary Cancer test has three main sections which are summarized in the banner on the first page. Throughout the report, these sections can be identified by the title on the top left of each page of the report.

1. Genetic result
2. Clinical & cancer family history information
3. Management tool

1 Genetic result

The MyRisk test looks at multiple genes associated with hereditary cancer risk. When a gene has a clinically significant mutation, or harmful change, there is a higher chance for certain cancers to develop. A list of the genes evaluated on your test can be found in this section of your report. The gene table on our website includes information about each gene and the cancers with which it is associated.

Your genetic result was POSITIVE.
This means that a clinically significant mutation, or harmful genetic change, was found in one or more of the genes analyzed as part of your testing. Since genes are passed down in families, your close relatives, such as your children, brothers and sisters, parents, aunts and uncles, and cousins, are at risk to have the same genetic change that was identified in you. It is important to share your results with your relatives so they can discuss genetic testing with their own healthcare providers.

If a variant of uncertain clinical significance (VUS) was identified, it will also be listed in the genetic result section. A VUS is a genetic change that may or may not be contributing to your cancer risk. A VUS is not considered to be clinically actionable, so medical care decisions should not be made based on a VUS. We are committed to identifying information so that we can better understand these genetic changes. If new information is available about your specific VUS, that information will be shared with your healthcare provider.


CONFIDENTIAL

MyRisk™ Hereditary Cancer Test

MyRisk Genetic Result

Hereditary Cancer Test

RECEIVING HEALTHCARE PROVIDER
Test HCP, MD
Test Medical Center
6689 BLANCO RD STE 200
SAN ANTONIO, TX 78216

SPECIMEN
Specimen Type: Blood
Draw Date: Dec 03, 2021
Accession Date: Dec 03, 2021
Report Date: Dec 03, 2021

SATIENT
Name: Pt Last Name, Pt First Name
Date of Birth: Dec 03, 1976
Patient ID: Patient id
Gender: Female
Accession #: 07007253-BLD
Requisition #: 90026822

GENETIC RESULT : POSITIVE - CLINICALLY SIGNIFICANT MUTATION IDENTIFIED
Note: "CLINICALLY SIGNIFICANT," as defined in this report, is a genetic change that is associated with the potential to alter medical intervention.

CLINICAL HISTORY ANALYSIS: NO ADDITIONAL MANAGEMENT GUIDELINES IDENTIFIED BASED ON THE CLINICAL HISTORY PROVIDED
Other clinical factors may influence individualized management. This analysis may be incomplete if details about cancer diagnoses, ages, family relationships or other factors were omitted or ambiguous. If this patient also has a clinically significant mutation, the recommendations based on the clinical history analysis should be considered in light of the possibility that this mutation explains all or some of the cancer history in the family.

GENE	MUTATION	INTERPRETATION
Gene Name	Mutation Name	High Risk This patient has Hereditary Breast and Ovarian Cancer syndrome (HBOC).

DETAILS ABOUT: *BRCA2* c.1163_1164dupTA (p.Pro3897Tyrfs*11): NM_000059.3; (aka: 1392insTA)

Functional Significance: Deleterious - Abnormal Protein Pr<180&n and/or Functs<

The heterozygous germline *BRCA2* mutation c.1163_1164dupTA is predicted to result in the premature truncation of the *BRCA2* protein at amino acid position 399 (p.Pro3897Tyrfs*11).

Clinical Significance: High Risk

This mutation is associated with increased cancer risk and should be regarded as clinically significant.

ADDITIONAL FINDINGS: NO VARIANT(S) OF UNCERTAIN SIGNIFICANCE (VUS) IDENTIFIED

Details About Non-C6;o0.lj Significant Variants: All individuals carry DNA changes (i.e., variants), and most variants do not increase an individual's risk of cancer or other diseases. When identified, variants of uncertain significance (VUS) are reported. Likely benign variants (Favor Polymorphisms) and benign variants (Polymorphisms) are not reported and available data indicate that these variants most likely do not cause increased cancer risk. Present evidence does not suggest that non-clinically significant variant findings be used to modify patient medical management beyond what is indicated by the personal and family history and any other clinically significant findings.

* ariant Classification: Myriad's myVision™ Variant Classification Program performs ongoing evaluations of variant classifications. In certain cases, healthcare providers may be contacted for more clinical information or to arrange family testing to aid in variant classification. When new evidence about a variant is identified and determined to result in clinical significance and management change, that information will automatically be made available to the healthcare provider through an amended report.

Positive results with SINGLE SITE testing: If a member of your family has tested positive for a clinically significant mutation, your provider may have ordered testing for only that specific genetic change. This is known as single site testing. Your positive result means that you DO carry the same harmful genetic change that was found in your family member and you should discuss any changes to your medical management that should be considered with your healthcare provider. Since single site testing does not look for other genetic changes or assess additional risk from family history, this is not a comprehensive risk assessment. Information in the management tool is specific ONLY to the clinically significant mutation listed on your report.

Breast cancer Riskscore™

You may or may not see a breast cancer RiskScore and/or a Tyrer-Cuzick breast cancer risk assessment in this section of the report. These results are calculated for women who meet certain criteria and have never been diagnosed with breast cancer themselves.


CONFIDENTIAL

MyRisk Genetic Result
Name: Pt Last Name, Pt First Name DOB: Dec 03, 1982 Accession #: 07007255-BLD Report Date: Dec 03, 2021

Breast Cancer RiskScore®

Breast Cancer RiskScore®: 35.3%

RESULT: 35.3% Remaining Lifetime Breast Cancer Risk
1.7% 5-Year Breast Cancer Risk

Remaining Lifetime Breast Cancer Risk (Age-Adjusted)

General Population 13.0%
20% Risk Threshold
This Patient 35.3%
0 5 10 15 20 25 30 35 40 45 50

BREAST CANCER RISKSCORE® INTERPRETATION

The breast cancer RiskScore provides an estimate of the remaining lifetime risk for breast cancer. A risk estimate at or above 20% is associated with specific modified medical recommendations, including consideration of more aggressive breast cancer screening and additional risk reduction measures. If applicable, details of these recommendations are provided in the accompanying MyRisk Medical Management Tool in the supplemental material. Women with a risk estimate below 20% may still be appropriate for increased

2 Clinical & cancer family history information

The Clinical & Cancer Family History Information section reviews the medical information that your healthcare provider gave us about you and your family. Certain types of cancer in the family or cancers diagnosed at early ages can indicate that someone may have an elevated risk, even if no clinically significant mutations are found.


CONFIDENTIAL

MyRisk™ Hereditary Cancer Test

Clinical & Cancer Family History Information

MyRisk™ Hereditary Cancer Test

RECEIVING HEALTHCARE PROVIDER
Test HCP, MD
Test Medical Center
6689 BLANCO RD STE 200
SAN ANTONIO, TX 78216

SPECIMEN
Specimen Type: Blood
Draw Date: Dec 03, 2021
Accession Date: Dec 03, 2021
Report Date: Dec 03, 2021

SATIENT
Name: Pt Last Name, Pt First Name
Date of Birth: Dec 03, 1976
Patient ID: Patient id
Gender: Female
Accession #: 07007253-BLD
Requisition #: 90026822

PERSONAL / FAMILY CANCER HISTORY SUMMARY

FAMILY MEMBER	CANCER / CLINICAL DIAGNOSIS	AGE AT DIAGNOSIS
Patient	None	
Family History	None	

PATIENT CLINICAL HISTORY SUMMARY

Woman's age	45	Hormone Replacement Therapy (HRT)	Not Specified
Ancestry	White/Non-Hispanic	HRT, Treatment Type	Not Specified
Weight	Not Specified	Number of years ago started	Not Specified

3 Management tool

In this section of the result, there will be a table for each gene in which a clinically significant mutation was identified. This table outlines associated cancers and the risk to develop these cancers. In another table, a summary of medical management options from expert medical groups for these cancers and/or a list of other health problems associated with the mutation are included. The medical management options may include changes to screening frequency or recommendations for a specific type of screening, discussions about preventive surgery, consideration of preventive medication, and/or lifestyle changes.

In addition to the genetic result, the presence of certain cancers in the family or certain medical findings in your own health history can also influence your cancer risk. There may be additional recommendations listed in this section due to these personal or family history health factors. If there are recommendations for changes to your breast cancer screening based on your RiskScore™ and/or a Tyrer-Cuzick breast cancer risk assessment, they will be included in this section. Personal and family histories can change over time, so it is important to keep your healthcare providers up to date regarding any changes.


CONFIDENTIAL

MyRisk™ Hereditary Cancer Test

MyRisk Management Tool

MyRisk™ Hereditary Cancer Test

RECEIVING HEALTHCARE PROVIDER
Test HCP, MD
Test Medical Center
6689 BLANCO RD STE 200
SAN ANTONIO, TX 78216

SPECIMEN
Specimen Type: Blood
Draw Date: Dec 03, 2021
Accession Date: Dec 03, 2021
Report Date: Dec 03, 2021

SATIENT
Name: Pt Last Name, Pt First Name
Date of Birth: Dec 03, 1976
Patient ID: Patient id
Gender: Female
Accession #: 07007253-BLD
Requisition #: 90026822

GENETIC RESULT : POSITIVE - CLINICALLY SIGNIFICANT MUTATION IDENTIFIED
Note: "CLINICALLY SIGNIFICANT," as defined in this report, is a genetic change that is associated with the potential to alter medical intervention.

CLINICAL HISTORY ANALYSIS: NO ADDITIONAL MANAGEMENT GUIDELINES IDENTIFIED BASED ON THE CLINICAL HISTORY PROVIDED
Other clinical factors may influence individualized management. This analysis may be incomplete if details about cancer diagnoses, ages, family relationships or other factors were omitted or ambiguous. If this patient also has a clinically significant mutation, the recommendations based on the clinical history analysis should be considered in light of the possibility that this mutation explains all or some of the cancer history in the family.

GENE	MUTATION	THIS GENETIC TEST RESULT IS ASSOCIATED WITH THE FOLLOWING CANCER RISKS:
Gene Name	Mutation Name	HIGH RISK: Breast, Ovarian, Pancreatic

Resources

Your healthcare provider is always your primary resource. You can find additional information and educational material at **www.mysupport360.com.**

You can request a consultation with a genetic counselor at Myriad by going to **my.myriad.com/consults**. During your consultation, the genetic counselor can help you understand your report and the implications of your results.

To view the full list of genes available on the MyRisk™ panel, please visit: **www.myriadmyrisk.com/gene-table/**

MYSUPPORT360®

Next steps

Schedule any follow-up appointments and/or obtain referrals to appropriate specialists

Speak with your relatives about your results and encourage them to see their healthcare provider about cancer prevention and genetic testing

Consider speaking with a **clinical genetic counselor** or other genetics expert in your community about your test result and family history

Myriad genetics

Myriad Genetics, Inc.
320 Wakara Way
Salt Lake City, UT
84108

myriad.com

MGMRHCPOSVPET / 02-22